Wegovy medication interactions: what the evidence says

Why gastric emptying is the central mechanism

The semaglutide in Wegovy activates GLP-1 receptors in the gut and brain, slowing the rate at which the stomach empties. That is largely why it reduces appetite, food stays with you longer. The same mechanism, though, creates a pharmacokinetic knock-on effect for oral medicines taken at the same time: if a tablet or capsule is still sitting in a stomach that empties slowly, it may be absorbed later, or absorbed to a lesser extent, than expected.

For most everyday medicines this matters little in practice. The concern rises sharply with drugs that have a narrow therapeutic index, medicines where a small shift in blood levels means the difference between effective treatment and toxicity. The NHS patient information for semaglutide specifically flags this and advises telling your prescriber about everything you take before starting. Your prescriber may adjust timing, monitor more closely, or reassess whether Wegovy is appropriate alongside a particular drug.

The delay in gastric emptying is most pronounced in the first few weeks of treatment and after dose increases, when GI effects are generally strongest. Separating oral medicines by an hour from any food or drink (and from semaglutide's own gastric effects) is a common practical step, but the specific management plan belongs with your prescriber, not a generic article.

Blood-glucose medicines and hypoglycaemia risk

Semaglutide lowers blood glucose. When combined with other medicines that do the same (particularly insulin or sulfonylureas such as gliclazide or glipizide) the combined effect can push blood sugar lower than intended. The clinical literature on GLP-1 receptor agonists documents this risk clearly, and the BNF entry for semaglutide lists concurrent sulfonylurea use as requiring monitoring and possible dose reduction of the other agent.

For people with type 2 diabetes starting Wegovy for weight management, the prescriber will usually review insulin or sulfonylurea doses proactively, not reactively when symptoms appear. Signs of hypoglycaemia (shakiness, sweating, confusion, rapid heartbeat) are worth knowing before you start, and your prescriber should run through them with you. This is also why the consultation process at a regulated service covers your diabetes history in detail; it is not box-ticking, it is the clinical step that keeps you safe.

Metformin, the most widely used diabetes medicine, does not significantly raise hypoglycaemia risk when used alongside semaglutide and is generally continued unchanged. SGLT-2 inhibitors (flozins) are also commonly used alongside GLP-1 medicines without a dramatic interaction signal, though your full picture always warrants individual review.

Oral contraceptives, HRT and other time-sensitive medicines

This is a question our prescribers hear regularly, and the evidence is genuinely nuanced. For Wegovy specifically, current NHS guidance does not identify the same oral contraceptive absorption concern that exists for tirzepatide (Mounjaro). With tirzepatide, NHS England advises adding a barrier method for the first four weeks of treatment and for four weeks after each dose increase; the equivalent instruction is not mirrored in the current semaglutide guidance. That said, if you take a combined or progestogen-only pill (particularly a low-dose formulation) discussing this with your prescriber before starting is the right step rather than assuming no action is needed.

HRT is a similar conversation. NHS England notes that for tirzepatide users, switching to transdermal HRT (patches or gels rather than tablets) removes the oral-absorption variable. For semaglutide, the evidence base is less explicit, but prescribers often apply the same precautionary logic for oral oestrogen preparations. If you use HRT alongside Wegovy, your GP and your weight-loss prescriber both need to know.

Levothyroxine is another medicine worth flagging. It is typically taken on an empty stomach first thing in the morning, and any change to gastric emptying could theoretically affect its absorption. NHS thyroid guidance already recommends separating it from food, coffee and other medicines; on semaglutide, your endocrinologist or GP may want to recheck your thyroid levels a few weeks after starting. Our page covering what medications interact with Wegovy goes into further detail on narrow-index medicines such as warfarin, where INR monitoring is sensible when starting or stopping any new medicine, including Wegovy.

Medicines, supplements and over-the-counter products worth mentioning

The interaction conversation should not stop at prescription-only medicines. Orlistat (the weight-loss medicine that blocks fat absorption) is incompatible with Wegovy both practically (it can worsen GI side effects) and clinically (combining weight-loss medicines is outside the licensed indications). If you are on a different weight-management approach, that needs to be disclosed at consultation.

Some supplements have their own glucose-lowering properties: berberine and chromium picolinate, for example, are taken by some people alongside GLP-1 treatment without formal prescriber oversight. Neither has been studied rigorously alongside semaglutide, and the blood-glucose interaction potential is non-trivial. Herbal preparations (St John's Wort in particular) can affect a wide range of medicines through CYP enzyme pathways; tell your prescriber about these too, even if they feel minor.

Alcohol is not a medicine, but it lowers blood glucose and can intensify GI side effects during the early weeks of semaglutide treatment. It is not prohibited, but moderation and awareness of how you feel are sensible.

The cost of a private consultation through a regulated service (and what is typically included) is covered on our Wegovy price page, which gives a realistic picture of the market. If you are ready to have your medication list reviewed by a prescriber, you can check your eligibility through a free consultation at our treatment page.